ROCURONIUM BROMIDE INJECTION SOLUTION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

ROCURONIUM BROMIDE

থেকে পাওয়া:

STERIMAX INC

এটিসি কোড:

M03AC09

INN (আন্তর্জাতিক নাম):

ROCURONIUM BROMIDE

ডোজ:

10MG

ফার্মাসিউটিকাল ফর্ম:

SOLUTION

রচনা:

ROCURONIUM BROMIDE 10MG

প্রশাসন রুট:

INTRAVENOUS

প্যাকেজ ইউনিট:

10X5ML

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

NEUROMUSCULAR BLOCKING AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0126317001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2023-03-02

পণ্য বৈশিষ্ট্য

1
PRODUCT MONOGRAPH
PR
ROCURONIUM BROMIDE INJECTION
10MG/ML STERILE SOLUTION FOR INJECTION
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
Strides Pharma Canada Inc.
1565, Boul. Lionel-Boulet
Varennes, Quebec
Canada J3X 1P7
Submission Control No.: 239118
May
14
, 2020
Date of
Revision:
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................................
3
SUMMARY
PRODUCT
INFORMATION
...........................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.................................................................................................................
3
CONTRAINDICATIONS
.......................................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
.....................................................................................................................
4
ADVERSE
REACTIONS
.......................................................................................................................................
8
DRUG
INTERACTIONS
......................................................................................................................................
10
DOSAGE
AND
ADMINISTRATION
..................................................................................................................
12
OVERDOSAGE
....................................................................................................................................................
17
ACTION
AND
CLINICAL
PHARMACOLOGY
..............................................................................................
17
STORAGE
AND
STABILITY
.............................................................................................................................
24
SPECIAL
HANDLING
INSTRUCTIONS
............................................................................................